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Abstract:
Objective: To assess the ability of vitamin D supplementation in preventing
musculoskeletal fractures. Methods: Systematic literature review using Google
Scholar search terms “vitamin D supplementation” and “preventing hip fractures” from
2006-2015. Only RCTs, meta-analysis, and clinical guidelines were included. Results:
Our search resulted in one meta-analysis and two randomized controlled trials.
Conclusion: The summation of our investigation into vitamin D deficiency and the
presence of musculoskeletal fractures has proven to be relatively inconclusive. The
resulting data from our three studies did not provide any definitive proof that improved
vitamin D levels correlates with better bone health.
Introduction:
The current issue surrounding the screening for vitamin D deficiency focuses on a
lack of accepted standards for classification and assessment. The United States
Preventive Services Task Force (USPSTF), an independent, volunteer panel of national
experts on prevention and evidence-based medicine, released a statement in 2014 on its
recommendations for vitamin D deficiency screening in adults, stating there was
insufficient evidence to assess the efficacy of such screening. Their statement
presented multiple industry wide inconsistencies that related to establishing valid vitamin
D comparisons. 25 hydroxyvitamin D (calcidiol or 25 OH-D) is the inactivated form of
vitamin D that is measured in serum. Various industry constituents classify “deficiency”
at different levels - Endocrine Society (<20 ng/mL); Institute of Medicine (<20 ng/mL);
National Osteoporosis Foundation (<30 ng/mL); United States Preventative Services
Task Force (<30 ng/mL). A lack of continuity creates confusion as to who is deficient
and who is not. Testing for 25 (OH)-D has numerous assays such as competitive protein
binding, immunoassay, high performance liquid chromatography or combined high
performance liquid chromatography and mass spectrometry. Sensitivity and specificity
for these tests are unavailable due to lack of a reference standard for comparative
analysis. Further variability exists among testing laboratories assay methods and the
ranges used per patient sex and ethnicity. 1 There is concern that vitamin D deficiency is
associated with increased risk of obtaining fractures and osteoporosis as we age. This
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paper aims to explore the efficacy of Vitamin D supplementation for prevention of
musculoskeletal fractures.

Case: BR is a 55 year old Caucasian female inquiring today about vitamin D
supplementation because she heard from a friend that it will help reduce the risk of
getting a hip fracture. She has no symptoms and no significant past medical history but
has a family history of osteoporosis. Physical examination is unremarkable. Vitamin D
screening reveals vitamin D level of 20ng/mL. We are interested to see if
supplementation of vitamin D will help reduce her risk of obtaining a hip fracture.
Patient/Population – Patients over the age 65 years old
Intervention – Vitamin D supplementation
Comparison – No supplementation
Outcome -- Preventing musculoskeletal fractures
Clinical Question: In patients ages 65 years and older with Vitamin D Deficiency, is
Vitamin D supplementation compared
to no supplementation beneficial for
preventing musculoskeletal fractures?

Methods:
We started our database
search using PubMed through the
James Madison University library
database. Our search terms included
“vitamin D” and “screening.’” We
refined our search to include ages 19
years and older, English language,
and published within the past 5 years
yielding about 1800 articles. We
narrowed our search to include clinical
trials, controlled clinical trials, meta-analysis, clinical guidelines, and randomized control
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trials. We originally used 50 years old as our cut off age for inclusion. Due to a large
search result, we changed the age range to include only patients above age 65 years
old in hopes to narrow our search but still resulted in 963 articles. To further narrow our
search, we changed our search terms to (vitamin D AND screening) AND osteoporosis
to result in 232 articles. Upon initial screening, these articles were not directly related to
our clinical question, were performed in foreign countries, or were not accessible
through the university database.
We were more successful in our search using Google Scholar. We used search
criteria “vitamin D supplementation” and “preventing hip fractures” yielding 243 results.
We refined the search to include studies published from 2006-2015. An advanced
search using “allintitle”: “fracture” “vitamin D supplementation” resulted in 33 results and
another search using “allintitle”: “fractures” “vitamin D supplementation” with 49 results.
We chose one article from each of the searches. Our third article to be reviewed was
identified by searching the reference list of a Medscape article pertaining to vitamin D.

Results:
Study 1: Fracture Prevention with Vitamin D Supplementation – A Meta-analysis
of Randomized Controlled Trials. 2 Bischoff-Ferrari H, Willett W, Wong J, et al.,
Journal of the American Medical Association, May 11, 2005, Vol. 293, No. 18, pgs.
2257-2264

Objective:
The objective of this study was to estimate effectiveness of Vitamin D
supplementation to prevent fractures in adults over the age of 60 years old.

Design:
This is a meta-analysis of seven randomized controlled trials identified through
searching MEDLINE, Cochrane Controlled Trials Register and EMBASE databases,
between 1960 and 2005. Additional studies were also identified through expert
consultation, searching reference lists, and the use of medical subject headings.
Eligible studies included only double blind randomized controlled trials with a minimum
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of one year follow up period (with range of 12 to 60 months) and a mean age of 60 year
old patients. The use of oral Vitamin D supplementation, a minimum of one fracture,
disclosure of how the fractures were determined, and measurement of 25hydroxyvitamin D levels during follow up were also requirements to be included in the
analysis. The combined studies recruited community dwelling patients, elderly patients
living independently in apartments or housing, and nursing home patients resulting in a
mean age of 60 years. Studies were excluded if they were uncontrolled trials,
observational or animal studies, any condition that would cause for increased falls
(stroke, Parkinson disease, steroid therapy, etc), or use of any vitamin D metabolites.
A treatment group receiving vitamin D supplementation with or without calcium
supplementation was compared to a placebo group to determine the relative risk of hip
fracture or nonvertebral fracture. Of the seven Randomized Control Trials (RCTs)
analyzed, two trials administered a 400 IU/day dose to the treatment group while the
other five trials administered 700 to 800 IU/day dose. Four of the trials used between
500 and 1200 mg/day supplement of calcium along with the Vitamin D supplement while
the remaining three trials recommended intake of three dairy products a day to achieve
800 mg/day calcium intake. Only one control group was provided with a calcium
supplement. The outcomes were analyzed using the intention to treat analysis.

Results:
The results of the RCTs in
this meta-analysis were separated

Table 1. Hip Fracture Results
Hip Fracture

RR

Q Test (P value)

Pooled Data

0.88

0.09 Heterogeneity

0.74

0.74 Homogeneity

1.15

0.68 Homogeneity

NNT

to include a hip fracture category
and a nonvertebral fracture category

Stratified Data

to be analyzed separately. The

High Dose (700-

relative risk for preventing hip

800 IU/d)x

fractures compared to any
nonvertebral fracture at any vitamin

Low Dose (400
IU/d)

D dose were 0.88 and 0.83,
respectively. There was a
significant degree of heterogeneity

RR = relative risk
NNT = number needed to treat

45
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Table 2. Non-vertebral fracture results.

observed in the hip fracture group and the
nonvertebral fracture group as evidence

Non-Vertebral

RR

Q Test (P value)

0.83

0.07

NNT

Fracture

by the Cochran Q test (P=0.09 and
P=0.07 respectively) and the L’abbe plot

Pooled Data

Heterogeneity

(Figure 3 of original meta-analysis). 2
Heterogeneity was defined using the cut
off value P<0.10.
The hip fracture and nonvertebral

Stratified Data
High Dose (700-

0.77

0.41

1.03

0.36

27

800 IU/d)

fracture results were then stratified into
Low Dose (400

separate dose categories to include a low

IU/d)

dose (400 IU/day) and high dose (700-800
IU/day) group. Upon stratifying the data,
homogeneity was observed (evidence in

RR = relative risk
NNT = number needed to treat

forest plot in Figure 2 of original meta-analysis) assuming there is similar variance
across the studies. 2 The results for each group are summarized in Table 1 and Table
2. For those treated with high doses vitamin D,
the number needed to treat based on the pooled

Table 3. Sensitivity Analysis for Hip and

risk difference is 45 for experiencing a hip

Non Vertebral Fractures

fracture and 27 for experiencing a nonvertebral
fracture. This indicated that 45 participants need
to be treated with 700-800 IU/d of vitamin D for

Relative risk for Hip Fracture
Pooled data

RR = 0.87

High dose

RR = 0.73

Low dose

RR = 1.15

24-60 months to prevent one person from

Relative Risk for Non Vertebral Fractures

obtaining a hip fracture and 27 participants

Pooled data

0.83 (P value = 0.13)

treated to prevent a nonvertebral fracture for 12-

High dose

0.77 (P value = 0.40)

60 months.

Low dose

0.93 (P value = 0.12)

A sensitivity analysis was performed in addition to the primary analysis to include
studies that were excluded from the primary analysis. The sensitivity analysis included
two trials that resulted in only one hip fracture and three trials that were less precise in
meeting the inclusion criteria. These results are summarized in Table 3. Additional
analysis of calcium intake and length of follow up were attempted, resulting in
inconclusive evidence. Calcium intake was not provided in the low dose vitamin D trials
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while all but one trial of the high dose trials were given between 500 to 1200 mg of
calcium to be taken daily.

- Bischoff-Ferrari, Willett, Wong, Giovannucci, Dietrich, Dawson-Hughes. Fracture prevention with vitamin D
supplementation. JAMA. 2005;293(18).

Overall, results of this meta-analysis suggest Vitamin D administered at higher
doses reduce hip fractures by 26% and nonvertebral fractures by 23%, based on the
calculated relative risks. Lower dose Vitamin D does not show to have favorable
outcomes in reducing fractures.

Critique:
This meta-analysis includes seven RCTs, each with large sample sizes to include
9,280 participants in total. Larger sample sizes are more effective in representation of
the population. Other strengths of this study include the age range which is pertinent to
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our target population in our research question, inclusion of males and females, and
double blinding randomization.
The sensitivity analysis that was performed to include 3 additional studies
regarding non-vertebral fractures nearly doubled the number of participants. The
relative risks for any non-vertebral fracture remained the same for the pooled data and
high dose group while the relative risk in the low dose group decreased to 0.93. These
results are consistent with the primary analysis and increase the sample size to
increase statistical power.
Negative attributes include the use of non-English, non-US studies and the age
of the meta-analysis. The use of non-English, non-US studies impedes data
extrapolation because they may not pertain to our patient population as there may be
different risk factors for osteoporosis and vitamin D deficiency in other parts of the
world. This article was published in 2005 and analyzes studies that were performed
between 1993 to 2004, which are over a decade old. Current research has conflicting
views with the recommendations of daily levels of vitamin D that should be consumed.
This research used daily doses of 400 IU/day of vitamin D, which was the
recommendation for adequate bone health at that time. The 2010 recommendations for
daily vitamin D ingestion, per the Institute of Medicine (IOM) and the National
Osteoporosis Foundation (NOF), consist of higher values. The IOM recommends 600
IU/day for individuals 18-70 years old and 800 IU/day for individuals 70 years or more.
The NOF recommendations are even higher with 800-1,000 IU/day for individuals 50
years or older.
Cochran Q test is a statistic based on the Chi squared test. Limitations to this
statistic are its poor power for determining true heterogeneity, hence the P value for
significance is 0.10 (rather than 0.05). 3 Additional limitations to the Q test are that it
does not give information regarding the strength between the variables, and it is
sensitive to the sample size of the studies. 4 Q tests have low power when there are too
few studies and high power with too many. Rather than using the Cochran Q test, the
more recently developed I2 value is more reliable and more commonly preferred.
Lastly, not all of the studies stratified their data according to sex, and all trials
were performed on predominantly white populations so data is limited, pertaining to the
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benefit in different genders and races. The independent effect of vitamin D could not be
determined due to the additional calcium administration being inconsistent among the
studies. Follow up period for inclusion in this meta-analysis required one year with an
average of about 2 years. There could be some question whether that is an adequate
duration for positive results.
Study 2: Calcium plus Vitamin D Supplementation and the Risk of Fractures. 5
Jackson R, La Croix A, Gass M, et al., New England Journal of Medicine, February 16,
2006, Vol. 354, No. 7, pgs. 669-683

Objective:
The objective of this paper was to assess the primary hypothesis that
postmenopausal women randomly assigned to a calcium plus vitamin D
supplementation group versus a control group would reduce the risk of fractures,
specifically hip fractures with further consideration of clinical vertebral fractures or lower
arm/wrist fractures.

Design:
This study consisted of 36,282 postmenopausal women, ages 50 to 79 years of
age, that were randomly assigned by double blind fashion to active supplementation of
1,000 mg calcium and 400 IU vitamin D3 per day (n=18,176) versus a placebo group
(n=18,106). The trial began with subject allocation between 1995 - 2000 and concluded
in 2005. Follow up took place over a nine year period (mean response of seven years).
These women were recruited from Women’s Health Initiative (WHI) Dietary Modification
trials, WHI Hormone Therapy trials or both. Exclusion criteria for trial prospects
included hypercalcemia, renal calculi, corticosteroid use, and calcitriol use. The trial did
allow for supplemental use of up to 1,000 mg Ca2+ per day and up to 600 IU vitamin D
per day, as well as bisphosphonates and calcitonin.
Baseline assessment, prior to randomization, consisted of a questionnaire
concerning calcium and vitamin D intake of dietary, supplemental and prescription
medication use. Blood samples of 25-hydroxyvitamin D levels were also acquired at
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this time. Bone mineral density was tested in a sub-group at randomization and at
annual visits 3, 6, and 9.
Participants were instructed to take chewable or swallowable tablets containing
500 mg of calcium carbonate and 200 IU of
vitamin D3 bi-daily with meals to maximize
absorption. Performance analysis was
investigated at six month phone calls or clinic
visits and at annual visits. Patient medication
compliance was assessed by weighing pill
bottles at clinic visits. 25-hydroxyvitamin D
levels were measured with DiaSorin Liaison
chemiluminescent immunoassay system.
Clinical fractures were recorded as any fracture
other than ribs, sternum, skull or face, fingers,
toes, or cervical vertebrae and were verified by
review of radiology, MRI or operative reports by
blinded, trained physicians.

Results:
The study ended in 2005 with 4.3% of the
study population being deceased and 2.7% lost
to follow up. Within the first three years of follow
up, adherence to the study medication regimen,
classified as continued use of 80% or more of
the study medication, was 60-63% and an
additional 13-21% were compliant with 50% of
the medication regimen. When the study ended,
76% were still taking some amount of the study
medication with 59% still adherent to the
originally prescribed levels of 80% or more.

- Jackson, LaCroix, Gass, et al. Calcium plus vitamin D

supplementation and the risk of fractures. New England Journal of Medicine. 2006;354(7):669-683.
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Bone mineral density (figure 2) of the total hip (A), total spine (B) and whole body (C)
were analyzed at annual visits 3, 6 and 9. Bone mineral density of the hip proved to be
the best outcome of the entire study with values in favor of treatment with calcium and
vitamin D. Average differences between treatment groups were 0.59% and 0.86% at
years 3 and 6 respectively (p-value - <0.001) and 1.06% at year 9 (p-value - <0.01).
Bone mineral density of the total spine and whole body were insignificant between study
groups.
Fracture analysis over the mean seven year follow up (intention-to-treat analysis)
saw a total fracture count of 2,102 for the calcium and vitamin D study group versus
2,158 within the placebo group (HR - 0.96). Hazard ratios (HR) are a measure of the
strength of a relationship produced by proportional hazard regression and may be
interpreted as a relative risk adjusted for multiple confounding variables. Hip fractures
of the study group consisted of 175, whereas the placebo group had 199 making this
the lowest hazard ratio of 0.88. Clinical vertebral fractures were 181 for the study group
and 197 for the placebo (HR - 0.90) and lower arm/wrist fractures were 565 for the
study group and 557 for the placebo (HR - 1.01). An additional comparison was made
between the treatment group and placebo group at six months after they were observed
to be noncompliant with the medication regimen. Hip fractures were found to have an
even lower hazard ratio of 0.71, with 68 fractures in the study group and 99 fractures in
the placebo group. No significant difference was found between the vertebral, lower
arm/wrist or total fracture groups.
Overall analysis found a higher likelihood of hip fracture for women in the age
group of 50-59 yo with a hazard ratio of 2.17 (95% CI - 1.13-4.18). Statistical
significance was also present with study group participants who had sustained zero falls
within the past 12 months with a hazard ration of 0.74 (95% CI – 0.56-0.98) versus one
fall with a hazard ration of 0.96 (95% CI – 0.62-1.49). The study medication regimen
was correlated with an adverse outcome of renal calculi found in 449 women in the
study group versus 381 women in the placebo group with a hazard ratio of 1.17 (95% CI
- 1.02-1.34).
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Critique:
Positive attributes that pertain to this article consist of a large study population
(n=36,282) which at the time, was the largest its size for this particular research. Bias
and influence was minimized and/or negated through the use of randomization of study
population allocation to specified research groups. There was an average of seven
years of follow-up for study participant analysis of research outcomes, which allowed for
a thorough understanding of the effectiveness of the implemented calcium and vitamin
D therapy. In relation to the assessment of bone mineral density, cross calibration of
the dual-energy x-ray absorptiometry machinery was measured to ensure comparability
of studies from the different testing centers.
Negative attributes in relation to this research starts with the release of this article
being almost a decade old. As addressed above, this is a cause for concern because
recommendations for daily vitamin D intake have changed over the past several years.
The diversity of this study was lacking with the study participants being 83% Caucasian.
Participants were allowed to use supplemental calcium and vitamin D outside the
amounts being administered, but there was no discussion of how they were accounted
for. Participants were also permitted to take other hormone medications such as
estrogen, bisphosphonates and calcitonin, as they were recruited from a Women’s
Health Initiative study. The additional supplements that may or may not have been
adequately accounted for and the hormone medications that could modify calcium and
vitamin D levels both have the potential to create variables that could alter the results of
this study.

Study 3: Treatment of Vitamin D Insufficiency in Postmenopausal Women - A
Randomized Clinical Trial. 6 Hansen K, Johnson E, Chambers K, et al., Journal of the
American Medical Association, August 3, 2015, Vol. 175, No. 10, pgs. 1612-1621

Objective:
The objective of this research article was to investigate the effects of high and
low dose cholecalciferol on total fractional calcium absorption (TFCA) – the percentage
of a given dose of calcium that is absorbed by the GI tract, bone mineral density (BMD),
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and muscle fitness after one year in postmenopausal women with vitamin D
insufficiency.

Design:
This study is a
randomized control trial
including 230
postmenopausal women
ages 75 and younger.
These women were
recruited via local

Table 4. Study Inclusion and Exclusion Criteria.
Inclusion Criteria


25(OH)D level of 14ng/mL – 27n/mL



>5 years post menopausal or oophorectomy



60 years or older if pervious hysterectomy w/o oophorectomy

Exclusion Criteria


>75 years old (associated with intestinal resistance to vit d)



Hypercalcemia

advertisements, and



Nephrolithiasis

eligibility was determined



Cancer w/in 5 years (excluding skin)

based on telephone



Inflammatory bowel disease

screening and screening



Malabsorption



Celiac sprue



Chronic diarrhea

serum
measurements of serum 25



Glomerular Filtration Rate < 45mL/min

(OH)D, calcium, albumin,



Adult fragility

creatinine and parathyroid



Fracture of hip, spine or wrist

hormone levels. Inclusion



Use of bisphosphonates, estrogens, calcitonin, teriparatide, oral
corticosteroids, anticonvulsants, or cholcalciferal >400IU/d

and exclusion criteria are
summarized in Table 4.
Eligible participants were



Diabetes mellitus



Bone mineral density T score -2.5 or less

educated to consume 600 to 1400 mg/d of calcium via diet or supplementation and
were advised to complete a 4 to 7 day diet diary within the first month of the study.
Participants were stratified by high Parathyroid hormone (PTH) level and calcium
intake greater than 1000 mg/d then were randomized into a high dose, low dose, or
placebo group. The high dose treatment group received a loading dose of 50,000IU/d
for the first 15 days to raise their 25(OH)D levels to above 30 ng/mL. The low dose and
placebo groups were also given a placebo loading dose for the first 15 days to maintain
masking. Following the loading dose administration: the high dose group was given a
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yellow high dose capsule to be given every 15th day with a white placebo capsule to be
taken daily, the low dose group was given a white low dose capsule to be taken daily
and a yellow placebo to be taken on every 15th day, and the placebo group was given
white capsules for daily consumption and yellow placebos for every 15th day.
Adherence was measured by counting the pre-filled pill boxes.
The primary outcome measured in this study was change in TFCA after one year
using the gold standard dual stable calcium isotope method (tracking of renal
reabsorption and endogenous fecal calcium excretion). BMD was the secondary
outcome measured, using the Lunar bone densitometry machine.
Participants followed up at 30, 60, 120, 240, and 365 days for 25(OH)D, calcium,
24-hour urine calcium levels, Timed Up and Go (TUG) (mobility assessment), and five
sit-to-stand (STS) tests (lower limb strength assessment). Also recorded at each visit
were pain rated on 10 point pain scale, functional
status, activity level, and adverse events (ex:
nephrolithiasis, fracture, infection, or hospitalization).
During analysis of the high dose treatment group, if any
of the participants’ 25(OH)D level dropped below 30
ng/mL then their cholecalciferol dose was adjusted to
reach the therapeutic range of greater than 30 ng/mL
(placebos were given to a group of the participants to
maintain masking).

Results:
Upon resolution of this one year study, nine
women (3.9%) had withdrawn due to personal reasons,
leaving the final study count at 221 participants. Mean
25 (OH)D serum levels showed considerable variance
between comparison groups at follow up visits. The
placebo group had a serum level of 19 ng/mL, low dose

- E. Hansen K, Erin Johnson R,

R. Chambers K, et al. Treatment of vitamin D insufficiency in postmenopausal women: A randomized clinical trial.
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cholecalciferol group had 28 ng/mL and the high dose cholecalciferol group had 56
ng/mL (p-value - < 0.001). The study participants had a near perfect compliance rate
with the medication regimen throughout the duration of the study.
TFCA was shown to increase in the high-dose study group (0.6%) and
decreased in the low-dose study group (4.5%) and placebo group (0.9%). Baseline
calcium absorption models were used to adjust for variance in baseline TFCA between
study groups. These models showed a 1% increase in the high-dose group and
decreases of 2% in the low-dose group and 1.3% in the placebo group.
No significance was found in comparison of groups in relation to bone mineral
density (Figure 3) for lumbar spine, hip or total body bone mass density, although a
minor change was noted in femoral neck bone mineral density.

Critique:
Strengths that can be credited to this study consist of it being a randomized,
double-blind, placebo-controlled trial which allowed for elimination of bias. This study
was published in 2015, so it is the most recent research conducted and is the most up
to date on recommended practices. Loss of participants was minimal with a 4% attrition
rate (9 individuals), while adherence rate to the research medication requirements was
100% with the remaining 221 individuals staying compliant throughout the entire study.
One of the major inclusion criteria was establishing baseline vitamin D deficient
participants (14-27 ng/mL) prior to starting the study to allow for a balanced comparison
between individuals. The study allowed personal calcium management of 600-1,400
mg/day which falls in line with current recommendation from IOM of 1,200 mg/day. This
research compared “low-dose” cholecalciferol of 800 IU/day (22,400 IU/mo) vs “highdose” 50,000 IU/ bi-monthly (100,000 IU/mo) vs placebo. Current recommendations
from the Institute of Medicine are 600-800 IU/day and the National Osteoporosis
Foundation are 800-1,000 IU/day. High level vitamin D therapy administration allowed
for a better understanding of potential outcomes according to current recommendations.
The exclusion criteria for this study was very thorough by prohibiting patients that had
diabetes mellitus; osteoporosis; hypercalcemia; nephrolithiasis; cancer within 5 years
(excluding skin CA); inflammatory bowel disease; malabsorption; celiac sprue; chronic
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diarrhea; glomerular filtration rate <45 mL/min; adult fragility; fracture of the hip, spine or
wrist; use of medications that modify bone integrity within the past 6 months
(bisphosphonates, estrogens, calcitonin, teriparatide, oral corticosteroids,
anticonvulsants or cholecalciferol doses greater than 400 IU/day); and bone mineral
density T-scores -2.5 or less.
This study presented with a few weaknesses worth mentioning. The study size
was considerably small (n=230) and took place in a single center in south-central
Wisconsin, which limits its ability to extrapolate data for greater populations. Its duration
took place over one year which doesn’t allow for greater insight into long term effects of
vitamin D therapy administration. The study population was poorly diversified with 90%
Caucasian, 6% African American, 2% Asian, 1% Indian/Alaskan, and 1% Hispanic and
is, therefore, limited in its applicability to more realistic populations. The research
focused primarily on bone mineral density and calcium absorption and had no
discussion of vitamin D deficiency’s effects on the presence of fractures, which is of
particular interest to our research. The study population was only women with a
maximum age of 75 years old which is limited in its applicability to our study population.

Discussion:
Vitamin D is important for bone health as it promotes calcium absorption,
maintains serum calcium and phosphate levels and allows for normal bone
mineralization. 7 Little evidence is available as to when the appropriate time to begin
screening for vitamin D deficiency and if the long term effects of supplementation are
beneficial. Although calcium is the most common contributor to osteoporosis, vitamin D
deficiency contributes equally by insufficient calcium absorption. 7 The purpose of this
review is to determine if supplementation of vitamin D is beneficial in preventing bone
fractures.
The results of the three studies varied, but each had a specific positive outcome.
All studies showed that the higher level vitamin D and calcium groups had better end
results than that of their comparisons. Bischoff et al showed that, after stratification, the
high dose vitamin D (700-80 IU/day) group had the lowest relative risk value with 0.74
for hip fractures versus its comparison group (400 IU/day) with a relative risk value of
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1.15. Jackson et al found that its supplementation group (vitamin D - 400 IU/day;
calcium - 1,000 mg/day) had better long-term total hip bone mineral density than
placebo group over the mean seven year follow-up period with mean differences
between study groups of 0.59% at year 3, 0.86% at year 6 and 1.06% at year 9.
Statistical significance was found at years 3 and 6 with a p-value of 0.001 and year 9
with a p-value of 0.01. Hansen et al demonstrated that, after controlling for baseline
calcium absorption levels, its high dose vitamin D group (100,000 IU/mo) had increases
of total fractional calcium absorption (TFCA) of 1% while the low dose group (800
IU/day) and placebo had decreases in TFCA of 2% and 1.3% respectively.
Jackson et al had the longest follow up period at seven years compared to
Bischoff et al with an average of 2 years and Hansen et al with one year follow up. A
seven year follow up period permits for thorough understanding of the effectiveness of
the implemented therapy. Jackson et al had its lowest hazard ratios among hip
fractures between the supplementation group and placebo of 0.71 (95% CI – 0.52-0.97)
when analyzing participants six months after being noncompliant with the medication
regimen. This hazard ratio increased to 0.88 (95% CI – 0.72-1.08) among the same
group when analyzed over the mean seven year follow up period. With shorter follow
up periods, there is inconclusive evidence regarding adequate time for a maximum
response to therapy.
Compliance in Jackson et al and Hansen et al were reported, but no data was
published regarding compliance for the individual meta-analysis studies. Hansen et al
had a considerably smaller sample size but nearly 100% compliance. Jackson et al
was significant for increased risk of renal calculi but also administered calcium 1,000
mg/day and allowed an additional calcium 1,000 mg/day at the discretion of the
participant, making it potentially the largest calcium administration of the three studies.
Jackson et al and a few of the RCTs included in the Bischoff et al meta-analysis
were provided with calcium supplementation which was regulated through the trial.
However, Jackson et al also allowed for the consumption of additional calcium,
bisphosphonates, and estrogen which were not accounted for throughout the study.
Hansen et al had strict exclusion criteria restricting the use of bisphosphonates,
estrogen, vitamin d >400 IU/d, calcitonin, etc. Although Hansen et al did not provide
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calcium supplementation to their treatment groups, they were recommended to
consume between 600-1400 mg/day.
There is currently no established definition of vitamin D deficiency with threshold
values existing between either <20 ng/mL to <30 ng/mL. Neither Bischoff et al nor
Jackson et al began their studies with stated baseline vitamin D levels for
inclusion/exclusion criteria, whereas Hansen et al established baseline vitamin D levels
for all participants of 14-27 ng/mL to create a uniform population for analysis.
There is currently no industry reference standard for testing for vitamin D. As
stated in the USPSTF, multiple assays exist such as competitive protein binding,
immunoassay, high performance liquid chromatography or combined high performance
liquid chromatography and mass spectrometry. Throughout our research, testing for
vitamin D was not similar between any of our studies. The first study did not define
which assays were used across any of the studies reviewed in the meta-analysis. The
second study stated that vitamin D was tested using the Dia Sorin Liaison
chemiluminescent immunoassay, while the third study used high performance liquid
chromatography. The third study claimed that its high performance liquid
chromatography assay is one of two gold standard assays, but the USPSTF statement
contradicts this claim. Without an established industry “gold standard” for cross study
comparison, there is no definitive way to make assertions that participant vitamin D
values are comparable.
Recommended daily vitamin D supplementation is also a debatable point. The
Institute of Medicine endorses daily vitamin D levels of 600 IU/day for ages 18-70 and
800 IU/day for older than 70 years. The National Osteoporosis Foundation suggests
800-1,000 IU/day for persons over the age of 50. These recommendations were
released in 2010. The first two studies were published in 2005 (Bischoff et al) and 2006
(Jackson et al), and the chosen vitamin D levels allotted to study participants were
commensurate with the recommended practice of the time. Bischoff et al consisted of
seven studies in total within the meta-analysis, with two studies administering 400
IU/day of vitamin D and the five other studies administering 700-800 IU/day, while
Jackson et al issued 400 IU/day of vitamin D to its participants. Hansen et al, however,
had a low dose (800 IU/day vitamin D) cohort and a high dose (100,000/month vitamin
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D) cohort. Comparing current recommendations to previously suggested therapeutic
levels would lend itself to increased vitamin D quantities being better for ideal bone
health. Unfortunately, none of these studies found convincing, statistically relevant data
that would support this assumption.

Table 5. Overall Comparison
Bischoff

Jackson et al

Hansen et al

9,280

36, 282

230

Age of

≥ 60

50-79 years

≤ 75 years old

participants

years old

old

Calcium

4 @ 500-

1,000 mg/day

600-1400 mg/day

400 IU/day

Low dose – 800IU/day

et al
Study
population

Administered

1,200
mg/day
3 @ 800
mg/day

Vitamin D

2 @ 400

administered

IU/day

High dose – 50,000 bimonthly

5 @ 700800IU/day
Duration of

Meta-

Study

analysis

1995-2005

2010-2014

7 years

1 year

~76%

Nearly 100%

19602005
Length of

Minimum

Follow up

one year
Average
~2 years

Compliance

N/A

Conclusion:
The summation of our investigation into vitamin D deficiency and presence of
musculoskeletal fractures has proven to be relatively inconclusive. The resulting data
from our three studies did not provide any definitive proof that improved vitamin D levels
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correlates with better bone health. Bischoff et al concluded that the use of vitamin D
700-800 IU/day would reduce the risk of hip or any non-vertebral fracture by
approximately 25% but did not correlate the benefit of calcium administration. Jackson
et al stated that following its research, calcium with vitamin D administration did improve
hip bone mineral density, but there was no statistically significant reduction in hip
fractures, nor clinical vertebral fractures, fractures of the lower arm or wrist, or total
fractures. Hansen et al made a final decision that due to their research, there was a
minor improvement of calcium absorption in the high dose vitamin D arm of their study
but realistically provided no meaningful benefits to overall bone mineral density.
Furthermore, they stated that a significant increase in calcium absorption is needed to
improve bone mineral density and reduce fracture risk.
The importance of screening tests is for the prevention of adverse health
outcomes. In relation to health screenings of vitamin D levels, the current lack of
industry standard for official classification of “deficiency” (<20 ng/mL vs < 30 ng/mL)
creates a subjective environment of one patient requiring supplementation, while
another would not. Furthermore, a “gold standard” assay has not been established to
allow for continuity between individual patient evaluations by separate practitioners.
Our research showed that there was no statistical significance between higher vitamin D
administration and fracture prevention but there was a positive correlation. A vitamin D
screening test might be in order for patients at a particular age, say 65 years old when
Medicare benefits can commence. This could provide baseline values on a practitionerby-practitioner basis for future assessment as osteoporosis and fall fractures become
more prevalent in older populations.
Our recommendation to BR about her inquiry into vitamin D supplementation for
reduction of hip fracture risk when she has a vitamin D level on the low end of normal (if
deficiency is classified as <20 ng/mL), is clinically asymptomatic, and has positive family
history for osteoporosis would be the positive “potential” benefits of supplementation.
This conversation could be framed with the understanding that there are no guarantees
about risk reduction, a positive correlation/association exists, and the only negative
outcome potential would be renal calculi.
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There is an upcoming clinical trial scheduled to begin in January of 2016, titled
“Effects of Vit D Fortification on Vit D Metabolite Profiles and Status in Vit D Insufficient
Individuals” (ID# - NCT02422784). Hopefully, this trial will provide more conclusive
evidence regarding the benefit of vitamin D to better provide clinically applicable
recommendations.
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